Regeneron Pharmaceuticals has faced a setback with the FDA rejecting its application for linvoseltamab, a treatment for a form of blood cancer. The rejection was due to issues related to a pre-approval inspection of a third-party manufacturer. Despite the setback, Regeneron remains committed to bringing linvoseltamab to patients, working closely with the manufacturer and the FDA.